Todd C. Brady

Todd C. Brady, M.D., Ph.D., a member of the board of directors, is the President and Chief Executive Officer of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) and a member of its board of directors. From April 2013 to December 2013, Dr. Brady also served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he served as a Principal. From 2002 to 2004, Dr. Brady was Senior Director of business development at Aderis Pharmaceuticals, Inc., a late-stage biotechnology company sold to Schwarz Pharma Mfg., Inc. (now UCB, Inc.) (EBR: UCB). Dr. Brady is a member of the board of directors of Evoke Pharma, Inc. (NASDAQ: EVOK), and of Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School (and serves on its Board of Visitors), a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.